Between the Lines is an engaging 30- to 45-minute open discussion showcasing insightful and impactful perspectives from oncologists and advanced practice providers on published, peer-reviewed content.
Between the Lines: Recent Updates in Treatment and Strategies for Managing Adverse Events in Multiple Myeloma
Larysa Sanchez, MD; and Samantha Shenoy, MSN, NP, discuss the management of adverse events with bispecific antibodies like GPRC5D and talquetamab while providing guidance on optimizing treatment outcomes and supportive care, as well as offering advice for managing toxicities and future perspectives on relapsed/refractory multiple myeloma.
T-DXd Demonstrated Intracranial Activity in HER2+ Breast Cancer
Belzutifan Has Durable PFS, ORR in Previously Treated Advanced Clear Cell RCC
Postsurgical Durvalumab Does Not Boost DFS in Lung Cancer
Understanding the Mechanism of Action Behind PARP Inhibitors for Prostate Cancer